Caprion Proteomics Inc.

Caprion Proteomics Inc. (Caprion) is a biotechnology company engaged in developing innovative drug delivery technologies for the treatment of cancer and infectious diseases. The company has developed its proprietary proteomics discovery technology platform CellCarta, used in profiling proteins in solid tissues and plasma. It also functions as a catalyst for disease target identification, predictive medicine as well as to discover and create therapeutic drug pipelines. Caprion has established research and licensing alliances in the oncology area with pharmaceutical companies under two domains namely novel target discovery and development, and biomarker discovery. It has partnership alliance with Abbott, Biogen Idec and ICOS, as well as a major bio-defense contract with the NIH on infectious disease target discovery program; where as in clinical plasma and tissue profiling the company works in alliance with Pfizer, AstraZeneca, Wyeth, Berlex and Vertex, for explaining the role of protein biomarkers in selecting the compounds and design of subsequent clinical trials. The product pipeline of Caprion consists of Shigamabs, a monoclonal antibody used for the treatment of shiga toxin-producing E. coli bacterial infections and CAP-232, a synthetic cyclic peptide with tumor killing potential. The company is headquartered at Montreal in Quebec, Canada.
In addition On january 22, 2010, the company aquires Biomaker service unit from PPD, Inc.